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ABSTRACT
Intrahepatic cholestasis of pregnancy (ICP) is cholestasis condition characterized by pruritus, elevated serum 
aminotransferase and bile acid levels with onset in the second or third trimester of pregnancy. Estimated of ICP 
prevalence only 0.001% to 0.3%. Bell's Palsy is a neurological disorder that causes facial muscles on one side 
of the face to suddenly weaken or become paralyzed. Bell's Palsy is more common in young adults, older people, 
diabetics and pregnant women. A 31-year-old women with major complaint is yellow eyes. She got itching  in all 
over the body. Patient was in second pregnancy with gestational age was 39-40 weeks. She suffered from unable 
to close her eyelid or blink. Patient was diagnosed with cholestasis intrahepatal in pregnancy and Bell’s palsy 
post partum. Diagnosis was established concluded from anamnesis, physical examination and hepar biopsy. 
The result of a liver biopsy showed intrahepatic cholestasis. From Fibroscan examination was visible with F2 
category or Moderate Fibrosis. The main management of this patient is cesarean section with ursodeoxycholic 
acid (UDCA) and corticosteroid therapy. Patient was administrated with antiviral therapy for her Bell’s Palsy 
condition. After 1 week hospitalization, patient was discharged with improvement of her major complaint. 
Keywords: intrahepatic cholestasis of pregnancy, post partum Bell’s palsy
ABSTRAK
Kolestasis Intrahepatik dalam kehamilan (KIK) adalah kondisi kolestasis yang ditandai oleh pruritus, 
peningkatan serum aminotransferase dan kadar asam empedu dengan onset pada trimester kedua atau ketiga 
kehamilan. Perkiraan prevalensi KIK hanya 0,001% hingga 0,3%. Bell's Palsy adalah gangguan saraf yang 
menyebabkan otot-otot wajah di satu sisi wajah tiba-tiba melemah atau menjadi lumpuh. Bell's Palsy lebih 
sering terjadi pada orang dewasa muda, orang tua, penderita diabetes dan wanita hamil. Seorang wanita 31 
tahun dengan keluhan utama adalah mata kuning dan gatal di seluruh tubuh pada kehamilan kedua dengan usia 
kehamilan adalah 39-40 minggu. Pasien juga mengeluh tidak bisa menutup kelopak matanya atau berkedip. 
Diagnosis kolestasis intrahepatik pada kehamilan dan post partum Bell's palsy ditegakkan dari anamnesis, 
pemeriksaan fisik dan biopsi hati  yang menunjukkan kolestasis intrahepatik. Pemeriksaan Fibroscan menunjukkan 
hasil F2 atau fibrosis sedang. Manajemen utama pasien ini adalah seksio sesaria dengan ursodeoxycholic acid 
(UDCA) dan terapi kortikosteroid. Pasien mendapatkan terapi antivirus untuk kondisi Bell's Palsy-nya. Setelah 
1 minggu dirawat di rumah sakit, pasien dipulangkan dengan perbaikan kondisi.
Kata kunci: kolestasis intrahepatik kehamilan, post partum Bell's palsy
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INTRODUCTION
Intrahepatic cholestasis of pregnancy (ICP) is 
cholestasis condition characterized by pruritus, elevated 
serum aminotransferase and bile acid levels with onset 
in the second or third trimester of pregnancy, and 
improvement of spontaneous signs and symptoms within 
two to three weeks after delivery. In the first description 
of ICP in 1883, Ahlfeld described pruritus and jaundice 
that occurred in the mother during the last trimester of 
pregnancy and disappeared after childbirth.1,2 Estimates 
of ICP prevalence in the United States are 0.001% 
to 0.32%, Chilean 4.0%, UK 0.7%, and Scandinavia 
1.0% to 2.0%. As for ICP, the prevalence of the disease 
varies according to ethnicity, and this is indicated by 
the prevalence in the UK (0.6% Caucassian, 1.5% 
Pakistanis, 1.2% South Asians). In the United States, 
the prevalence of ICP 5.6% in Hispanics.3
Pruritus is a major clinical symptom of ICP. Pruritus 
may be mild and tolerable for some patients, but may 
also be severe and have a serious impact. This may be 
very disturbing to the quality of life of patients who 
cause sleep deprivation, psychological suffering and 
even thoughts of suicide. Usually occurs in the third 
trimester, after 30 weeks of gestation, but rare and 
uncommon cases develop before that age.4,5,6 Mild 
Jaundice with conjugated bilirubin serum levels occurs 
only occasionally in 10 to 15% of cases.4,7 Jaundice 
is usually develops 1-4 weeks after onset of pruritus, 
but can sometimes be an early symptom.8,9 Subclinical 
steatorrhea may be seen simultaneously with fat 
malabsorption, which can lead to vitamin K deficiency 
resulting in prolonged protrombin time and postpartum 
hemorrhage.10,11 Higher incidence of gallstones and 
cholecystitis develops 4x in women with a history of 
ICP (as well as in families with a history of ICP) than 
in the normal population.12 Abdominal pain, malaise 
and other constitutional symptoms are rare. The major 
biochemical changes are increased serum bile acid and 
elevated aminotransferase levels.13 Total bile acid levels 
may increase 10-100 times above the normal range 
and higher rates of fetal complications are observed 
with rates of maternal bile acids exceeding 40 μmol/L. 
14,17,18,20 The serum aminotransferase level makes it 
possible to improve ICP patients after starting UDCA 
treatment compared with fasting serum bile acid levels 
initially increased due to elevated serum levels of 
urseodoxycholic acid (UDCA). The maternal prognosis 
improves and symptoms resolve rapidly after delivery, 
accompanied by normalized serum liver and bilirubin 
tests.22 If persistent abnormalities are found, prompt 
reconsideration of underlying chronic liver diseases 
such as primary biliary cirrhosis, primary sclerosis 
cholangitis, or chronic hepatitis C may all be associated 
with pruritic development late in pregnancy 24,25
 Bell's Palsy is a neurological disorder that causes 
facial muscles on one side of the face to suddenly 
weaken or become paralyzed. The eye-closing muscles 
control the tear glands, while controlling one of the 
salivary glands and the flavor in front of the tongue 
are all controlled by the facial nerve. When damage or 
trauma is caused to the facial nerve, it usually affects 
only one side of the face.26 Electrochemical signals sent 
from the brain to these muscles run along the facial 
nerve. If the facial nerve is disturbed, no signal can 
penetrate these muscles and depending on how many 
nerve fibers are in the involved facial nerve, half the 
affected face experiences muscle weakness or paralysis 
and this is what is known as Bell's Palsy.26 People with 
Bell's Palsy are distracted by normal facial actions and 
functions such as closing their eyes, eating, smiling 
and uttering their utterance. Other symptoms present 
include eye tearing, loss of taste, unclear speech, 
sensitivity to sound, facial paralysis and saliva. This 
condition occurs suddenly, and usually peaks within 
48 hours.27 Bell's Palsy affects about 40,000 people 
in the United States each year. Bell's Palsy is more 
common in young adults, older people, diabetics and 
pregnant women. Children are not immune to it but 
they tend to recover very well. Generally there are no 
other medical risks associated with this condition but 
the development of Bell's Palsy during pregnancy can 
be attributed to the development preeclampsia.27
CASE ILLUSTRATION
A 31-year-old Post Cesarean Section Women 
complained of yellow eyes since 3 days ago. 
Patients also complained of itching all over the body. 
Complaints of itching all over the body appear along 
with the appearance of yellow body and yellow eyes. 
She was pregnant with gestational age was 39-40 weeks 
when she admisssion to the hospital. She had normal 
labor when she had her first pregnancy and she didn’t 
complaint yellow eyes or yellow body when she got 
first pregnancy. From Physical examination, we found 
icteric sclerae and anemia conjunctiva with decrease of 
haemoglobin level (9.3 g/dL) and hiperbilirubinemia 
mainly direct (9.16 mg/dL). Increase of transaminase 
level happened with AST/ALT level (199/105U/L). 
Increase of ureum and creatinin level was 103.90/5.45 
mg/dL or azotemia renal. Hypoglicemia was happened. 
Hypoalbuminemia with 2.38 mg/dL happened too. 
Prolonged APTT level with 56.70 (control 25). 
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Patient was initial diagnosis with Gravida trimester 
3 with increased transaminase azotemia+ hypoglycemia 
+ prolonged APTT suspect dt Intrahepatic cholestasis 
of pregnancy differential diagnosis with AFLP 
and HELLP syndrome. At initial therapy, patient 
administrated with immediately Cesarean section. 
Patient was given oxygenation, D20 % 100 cc, UDCA 
250 mg and FFP Transfusion. Patient was planning 
diagnosis with Hepar biopsy and Fibroscan. After 
Cesarean section, patient administrated with giving 
metilprednisolone 62.5 mg intravenous a day. At 
second day post partum, patient complaint with her 
mouth had deviation to the left side. And her left eye 
couldn’t close and and wink. From neurology status, 
there was Parese N VII D LMN type house bruckmann 
4. Patient was diagnosed with Bell’s Palsy Partum.
Patient administrated with acyclovir 500 mg and 
B6 vitamin 25 mg. Metilprednisolone intravenous 
continued until seven days. After 7 days, patient 
was in stable condition and without any complaint. 
Patient was planned for hepar biopsy and fibroscan. 
Result from Pathology Anatomy was cholestasis 
intrahepatal. It showed fibrosis periportal appearance.
The diagnosis of cholestasis intrahepatal in pregnancy 
was established. Patient got fibroscan and the result was 
8 kpA which is means moderate fibrosis in cholestasis 
liver. 
DISCUSSION
Intrahepatic cholestasis of pregnancy (ICP) is a 
cholestatic disorder characterized by pruritus, elevated 
serum aminotransferase and bile acid levels with 
onset in the second or third trimester of pregnancy. 
Jaundice usually develops 1-4 weeks after onset of 
pruritus, but it can sometimes be an early symptom. 
The etiology that causes ICP can not be understood. 
Suspected genetic, hormonal, and environmental 
factors contribute to the pathogenesis of ICP. Suspected 
mutations in the hepatocellular phospholipid transporter 
ABCB4 (MDR3), which mediates the secretion of 
phosphatidylcholine (lecithine) into bile, is thought to be 
15% in the case of ICP. Thomas Et al mentions estrogen 
plays an important role in the incidence of ICP. ICP 
usually occurs at the end of the trimester when estrogen 
levels reach maximum levels. This is supported by the 
tendency of patients using oral contraceptive estrogen. 
Progesterone also contributes to the pathogenesis of ICP. 
Patients with ICP were significantly elevated plasma 
levels of mono or disulfated porgesterone metabolites. 
Some estrogen, glucuronide, and progesterone sulfate 
metabolites are known to cause cholestasis. In this case, 
the initial onset of this condition is form of a yellow 
eyes followed by itching at all over the body. Patients 
were gravida in the third trimester. Laboratory results 
showed increased bilirubin, especially direct bilirubin 
and increased serum aminotransferase that showing 
signs of cholestasis.
Thomas et al says hydrophilic bile acid 
ursodeoxycholic acid (UDCA) is the most effective 
therapy in ICP. An open randomized parallel study, 
84 patients with symptomatic ICP were randomly 
assigned to UDCA compared with 14 days of 
cholestyramine. The pruritus symptoms disappeared 
significantly with UDCA administration and also 
found to decrease effectively from levels of SGOT/
SGPT and bile acid levels. A double blind placebo 
controlled trial comparing UDCA administration (1 
g/day for 3 weeks) and dexamethasone (12 mg per 
day for 1 week) in 130 women with ICP significantly 
improved serum aspartate aminotransferase (AST)/
alanine aminotransferase (ALT) and bilirubin levels 
on UDCA administration. UDCA appears to have a 
tolerant impact on pregnant women and no adverse 
effects on mothers and babies born.UDCA provides an 
improvement on the canalular expression of a protein 
transporter, MRP2 or bile salt exporter that reduces the 
incidence of cholestasis. In this patient, UDCA 250 mg 
tablet and methylprednisolone 62.5 mg intravenous 
were administered.
she got first pregnancy. From Physical examination, we found icteric sclerae and anemia 
conjunctiva with decre se of haemoglobin level (9.3 g/dL) and hiperbilirubinemia mainly 
direct (9.16 mg/dL). Increase of transaminase level happ ned wit  AST/ALT level 
(199/105U/L). Increase of ureum and creatinin level was 103.90/5.45 mg/dL or azotemia renal. 
Hypoglicemia was happened. Hypoalbuminemia with 2.38 mg/dL happened too. Prolonged 
APTT level with 56.70 (control 25).  
Patient was initia  diagnosis with Gravida trimester 3 with increased transaminase 
azotemia+ hypoglycemia + prolonged APTT suspect dt Intrahepatic cholestasis of pregnancy 
differential diagnosis with AFLP and HELLP syndrome. At initial therapy, patient 
administrated with immediately Cesarean section. Patient was given oxygenation, D20 % 100 
cc, UDCA 250 mg and FFP Transfusion. Patient wa planning diagnosis with Hepar biopsy 
and Fibroscan. After Cesarean section, patient administrated with giving metilprednisolone 
62.5 mg intravenous a day. At second day post partum, patient complaint with her mouth had  
Figure 1. Result From Pathology Anatomy: cholestasis Intrahepatal. 
 Fibrosis periportal appearance 
Figure 1. Result From pathology anatomy: cholestasis 
Intrahepatal. Fibrosis periportal appearance
Figure 2. Result of Fibroscan: moderate fibrosis
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The maternal prognosis improves and symptoms 
resolve rapidly after delivery, accompanied by 
normalized serum liver and bilirubin tests. Delivery is 
recommended at 37-38 weeks' gestation. In this patient, 
after delivery in case, sectio caesarea, patient got 
improvement. Komal et al mentioned that cholestasis 
in histopathology was characterized by bile pigment 
in hepatic green liver parenchyma, degeneration 
of hepatocytes, bile duct proliferation seen from 
epithelial cell proliferation and presence of periportal 
neutrophils. Patient got hepar biopsy for established 
the diagnosis of cholestasis intrahepatal in Pregnancy. 
The result biopsy is: (1) Hepatocytes are cloudy 
degeneration; (2) Appearing bile pigment to cytopasm 
and canalysis, vague appearance of periortal fibrosis 
and piecemeal necrosis; (3) Conclusion: cholestasis 
intrahepatal; fibrosis periportal appearance.
Liver fibrosis as occurs in other organs depends on 
various factors. The main factor is the extracellular 
matrix of the organ. Extracellular matrix is  a structure 
that can change shape and structure that channel 
the power/impact from the outside to the heart. The 
second factor is the urgings that occur in the liver. The 
greater the pressure that occurs in the liver, the more 
fibrosis will occur. The third factor is pressure inside 
the organs, if blood or other flow comes in and out 
of the organ, the stiffness/fibrosis will depend on the 
resistance of the liver to the flow. The fourth factor and 
important factor is the effect of viscosity/ensity that 
affects the time constant when fibrosis is examined. 
And this effect is related to frequency. When the soft 
heart is with the low frequency it gets, it will become 
denser with high frequency. Fibroscan is a modality 
for assessing the magnitude of fibrosis (density or scar 
tissue of the liver). The result of Fibroscan with normal 
value limit is 2-7 kPa. The mean normal value is 5.3 
kPa With degrees of fibrosis divided by: (1) F0 which 
means no scarring; (2) F1 which means mild fibrosis; 
(3) F2 which means moderate fibrosis; (4) F3 which 
means severe fibrosis; (5) F4 which means cirrhosis 
or advanced fibrosis.
In this patient the result of fibroscan is 8 kPa for 
the fibrosis stage that means F2 category or moderate 
fibrosis in cholestasis liver. Bell's Palsy is more 
common in young adults, older people, diabetics and 
pregnant women. In this patient there was a sign of 
bell's palsy 2 days after the action sectio caesarea. 
Bell's Palsy causes palsy in the peripheral lower motor 
neurone area, with clinical manifestations of paralysis 
of the facial nerve with eye and mouth closure disorders 
and facial muscle movement disorders. A deficit in 
the central UMN can also cause weakness in the face. 
Patients with facial palsy require careful examination. 
Grading scale House Brackmann is a documentation 
for facial palsy Patient suffered from Parese N VII D 
LMN type house bruckmann 4.
The goal of bell's palsy management is mainly due 
to HSV's rapid recovery and prevention of corneal 
complications. Therapy should begin immediately to 
prevent replication of the virus and prevent prolonged 
effects that damage the facial nerve. Bell's palsy can be 
effectively treated with corticosteroids within the first 7 
days. A study suggests the benefit of steroid therapy is 
improvements in outcome obtained after corticostreoid 
administration within the first 72 hours. An antiviral 
therapy looks logical in Bell's Palsy due to the possible 
development of herpes virus. Aciclovir is an analogue 
nucleotide that inhibits the replication of viral DNA. In 
this patient, bell’s palsy therapy was given Acyclovir 
400 mg every 6 hour, Metilprednisolone 16 mg every 
6 hour and B6 vitamin 25 mg a day.
Patients was in third trimester of pregnancy. 
Laboratory results showed increased bilirubin, 
especially direct bilirubin and increased serum 
aminotransferase that showing signs of cholestasis. 
Patient administrated with  UDCA 250 mg every 8 
hours and metilprednisolone intravenous 62.5 mg a 
day. After cesarean section, condition of patient was 
improved significantly. The diagnosis from the patient 
was established by hepar biopsy that showed cholestasis 
intrahepatal appearance. Patient got fibroscan and 
showed moderate fibrosis in cholestasis liver.
Patient was diagnosed as Bell’s Palsy Post 
Partum after sectio caesarea operation. Patient was 
administrated with Acyclovir, metilprednisolone and 
B6 vitamin. And the condition of this patient was 
improved.
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